Synplicity ( SYNP) plummeted more than 27% in after-hours trading Thursday as the Sunnyvale, Calif.-based company guided lower than its previous forecast and below Wall Street expectations as well. The semiconductor-software company now expects revenue of $16.4 million for the Dec. 31, 2006, quarter, down from its previous range of $17.2 million to $17.7 million. Analysts polled by Thomson Financial are seeking $17.5 million. In addition, the company shaved a penny off the top of its earnings range, now expecting between 6 cents and 7 cents a share. However, this still covers the consensus estimate. Shares were losing $1.73 to $4.60. Enzon Pharmaceuticals ( ENZN) jumped on news that it had submitted an application to the Food and Drug Administration for the development of an antagonist drug that targets multiple cancer processes, including solid tumors, called HIF-1 alpha. The Bridgewater, N.J., company licensed the drug from Denmark-based Santaris Pharma in July 2006. Shares were rising 59 cents, or 7%, to $9. Learning Tree ( LTRE), which develops classroom courses for Internet technology professionals, gained on word of an expected rise in fiscal fourth-quarter results, as well as an earnings restatement that will probably fall in line with previously announced estimates to that effect. Profits from operations are projected at $200,000, which compares with a restated year-ago loss of $800,000, and revenue should rise 6% to $37.7 million. The analyst who follows the company is looking for $38.6 million.
Full-year results will be dimmer, with an expected loss from operations of $1.9 million, compared with a $1.6 million restated loss in 2005. However, full-year revenue will likely total $154 million, which just about meets the analyst's estimate. The company says the restatement -- which corrects accounting flaws related to discontinued operations in Britain -- widened losses from operations by about $900,000 for the first three quarters of 2006 and by about $500,000 in full-year 2005. Shares were up 34 cents, or 3.8%, to $9.39. RightNow Technologies ( RNOW) plunged after the Montana-based business software and services firm cut its fourth-quarter outlook. It now expects to lose more than its previously announced range of loss of 2 cents to break-even a share. Revenue is estimated at $28 million, at least $3 million below its prior prediction. Analysts are seeking income of 3 cents a share on sales of $31.4 million. Shares were losing $2.21, or 12.7%, to $15.20. Electro Scientific Industries ( ESIO) tumbled on disappointing fiscal second-quarter results. The Portland, Ore.-based company, which makes laser systems for microengineering applications, said it earned $3.8 million, or 13 cents a share, on revenue of $59.3 million in the quarter ended Dec. 2. This represents a steady rise from year-ago income of $3.2 million, or 11 cents a share, on $48.6 million in sales. Analysts, however, were looking for 16 cents a share on $58.8 million in revenue. Shares were off $1.34, or 6.5%, to $19.15.
Data-storage systems maker Xyratex ( XRTX) fell on narrowing profits for both the quarter and year ended Nov. 30. On a non-GAAP basis, the Britain-based company earned $10.9 million in the quarter, or 36 cents a share, compared with $15.5 million, or 54 cents a share, a year ago. Full-year non-GAAP earnings came to $64.9 million, or $2.17 a share, compared with $46.9 million, or $1.62 a share, a year ago. These figures topped the consensus estimates for the quarter and year -- 30 cents and $2.11, respectively -- but shares were still sliding 88 cents, or 4.3%, to $19.52. Healthways ( HWAY) slipped on disappointing revenue. The health care company saw profits of $11.8 million, or 32 cents a share, in the quarter ended Nov. 30, which met Street projections and compares favorably with year-ago earnings of $6.5 million, or 18 cents a share. Revenue rose a healthy 29% to $117.1 million but just missed analysts' $121.2 million estimate. Shares were falling $2.49, or 5.4%, to $43.25.